We investigated the mechanisms by which leukotriene receptor antagonists decrease airway eosinophil number. In a randomized, double-blind crossover study, we examined the effects of 2 weeks of treatment with pranlukast 300 mg twice a day or placebo on allergen-induced changes in airway eosinophil number and bone marrow eosinophil progenitors in 15 subjects with mild asthma. Pranlukast treatment for 2 weeks decreased mean sputum eosinophil count from 0.15 ϫ 10 6 /g (5.3% of cells) before treatment to 0.02 ϫ 10 6 /g (0.7% of cells) after treatment (p Ͻ 0.05), whereas placebo did not. Pranlukast also decreased the eosinophil count (5.6% at 7 hours and 7.5% at 24 hours) (p Ͻ 0.05) after allergen inhalation compared with placebo (13.8% at 7 hours and 15.3% at 24 hours). There was a similar trend for sputum cells immunostaining for EG2, eotaxin, interleukin-5, and regulated upon activation, normal T cell expressed and secreted. Pranlukast also significantly attenuated the allergen-induced increase in the number of bone marrow eosinophil/basophil cfu (mean 0.3) at 24 hours compared with placebo (mean 6.2). The proportion of CD34 ؉ cells expressing the eotaxin receptor CC chemokine receptor 3, 24 hours after allergen inhalation, was also reduced by pranlukast. We conclude that, the cysteinyl leukotriene receptor antagonist, pranlukast, attenuates allergeninduced increase in airway eosinophils by decreasing bone marrow eosinophilopoiesis and airway chemotactic and eosinophilopoietic cytokines.
way inflammation (7) . After an allergen inhalation, eosinophil lineage-committed progenitor cells expressing the membranebound isoform of IL-5 receptor ␣-subunit (CD34 ϩ IL5-R␣ ϩ ) and the IL-5-responsive eosinophil/basophil cfu (Eo/B cfu) increase in the bone marrow (8) (9) (10) and in peripheral blood (11) . Progenitor cells are also observed in the airway mucosa of subjects with asthma (12) . It is likely that allergen inhalation increases the number of eosinophil progenitors in the bone marrow, which migrate to the airways either as mature eosinophils or as immature cells and undergo local differentiation. An increase in the eotaxin receptor, CC chemokine receptor 3 (CCR3), on the bone marrow progenitor cells after an allergen inhalation may facilitate the progenitor cell mobilization from the bone marrow to the peripheral circulation (13) .
Cysteinyl leukotrienes promote airway eosinophilic inflammation. Inhalation of LTD 4 and LTE 4 causes sputum and tissue eosinophilia (14) , and cysteinyl leukotriene receptor antagonists can decrease sputum eosinophilia (15) . Cysteinyl leukotrienes can cause airway eosinophilia by a number of possible mechanisms (16) . They can promote eosinophil chemotaxis into the airway (17) , increase the surface expression of adhesion molecules on eosinophils and blood vessels facilitating their migration (18) , prolong eosinophil survival (19) , and upregulate gene expression of various cytokines/chemokines such as IL-4, IL-5, IL-13, eotaxin, and granulocyte-macrophage colony-stimulating factors that can promote eosinophil production and survival (20) . We have shown previously that bone marrow Eo/B cfu cultures grown in the presence of IL-5 were significantly increased by LTD 4 and this was inhibited by montelukast (21) . We therefore hypothesized that one of the mechanisms by which cysteinyl leukotrienes promote airway eosinophilia is by promoting eosinophilopoiesis in the bone marrow.
We investigated this by studying the effect of a cysteinyl leukotriene-1 receptor antagonist, pranlukast, on allergen-induced changes in bone marrow-derived eosinophil lineage-committed CD34 ϩ cells and IL-5-responsive Eo/B cfu. In addition, we studied the effect of treatment on CCR3 receptor expression on the progenitor cells. We also studied the effect of pranlukast treatment on the numbers of total and activated eosinophils in sputum and the immunoreactivity in sputum cells for EG2 ϩ , IL-5, eotaxin, and RANTES.
Some of the results of these studies have been reported previously in the form of an abstract (22) .
METHODS

Subjects
The subjects were 16 nonsmokers with atopy and mild asthma (Table  1) using short-acting ␤-agonists infrequently. All subjects gave written informed consent, and the Research Ethics Committee of Hamilton Health Sciences Corporation approved the study.
Design
This was a randomized, double-blind, crossover, two-period study comparing 2 weeks of treatment with pranlukast, 300 mg tablet twice a day, or matching placebo, with at least 2 weeks of washout period between the treatment periods. The subjects underwent a screening allergen inhalation to identify those with a dual asthma response (greater than 15% fall in FEV 1 within 120 minutes, followed by a similar drop between 3 and 7 hours after allergen inhalation). After 2 to 4 weeks, they had spirometry, sputum induction, and a methacholine inhalation test. They were then randomized to one of the two treatment arms using computerderived codes that were maintained off-site by an independent thirdparty pharmacist. (23) . Allergen inhalation was performed as described previously (2, 24) .
Sputum Induction and Processing
Sputum was induced with hypertonic saline, separated from saliva, and processed as described by Pizzichini and coworkers (25) .
Sputum Cytochemistry
Sputum cytospins were prepared on Aptex-coated slides (Sigma Chemical Co., Mississauga, ON, Canada), fixed for 10 minutes in periodatelysine-paraformaldehyde, and stained as described by Gauvreau and coworkers (1) .
Bone Marrow Progenitor Culture
Five milliliters of bone marrow sample was aspirated into heparinized (1,000 U/ml) syringes from the iliac crests after freezing the skin and periosteum with 2% lidocaine. Low-density mononuclear cells were isolated by sedimentation on Percoll density gradients (specific gravity 1.08) and cultured in the presence of IL-5 (1 ng/ml) as described previously (8-10).
Immunofluorescence Staining
Nonadherent mononuclear cells were stained with saturating amounts of biotin-conjugated anti-IL-5R␣, and anti-CCR3, or the isotype-control antibody in 100 l of ice-cold, fluorescence-activated, cell-sorter staining buffer for 30 minutes at 4ЊC (8, 9, 12, 13) .
Flow Cytometry
The stained nonadherent mononuclear cells were analyzed using a FACScan flowcytometer equipped with an argon laser (Becton Dickinson Instrument Systems, Mississauga, ON, Canada) using the CELL-QUEST program. CD34 ϩ blast cells were identified as described previously (8, 13).
Analysis
Demographic data were summarized using descriptive statistics. Sputum eosinophil counts, expressed in absolute terms and as a percentage of the total cell count, and the immunopositive cells were analyzed using repeated measures analysis of variance. Treatment (pranlukast or placebo), time (baseline, preallergen, 7 hours postallergen, 24 hours postallergen), and period (first or second treatment) were the within-subject factors. The differences between pranlukast and placebo on allergeninduced changes in bone marrow progenitor colony counts and receptor expression were analyzed using paired t test. All analyses were performed using the Statistical Package for Social Sciences, version 10 (SPSS Inc., Chicago, IL). p Values less than 0.05 were considered to be statistically significant.
RESULTS
One subject developed a facial urticaria after one dose of the study medication and was withdrawn from the study. Fifteen subjects completed the study. One subject had transient, mild, and reversible elevation of liver enzymes that was not attributed to pranlukast treatment. The overall compliance with treatment was 90%.
Sputum Cell Counts
Two weeks of treatment with pranlukast decreased mean sputum eosinophil count from 0. (Figure 1 ). There were no significant changes in the total sputum cell counts or other cell counts with either allergen inhalation or pranlukast treatment (data not shown).
Sputum Cytochemistry
Similar to the effect on eosinophil counts, 2 weeks of treatment with pranlukast decreased EG2 ϩ cells and attenuated the aller- Figure 1 . Changes in sputum eosinophil count. Two weeks of placebo treatment did not have any effect on the eosinophil count (expressed as a percentage of total cell count), whereas treatment with pranlukast decreased it significantly. The increase in eosinophil count at 7 and 24 hours after allergen inhalation was also significantly decreased by pranlukast treatment but not by placebo (*p Ͻ 0.05). gen-induced increase in EG2 ϩ cells ( Table 2 ). The effect at 7 hours was statistically significant compared with the placebo treatment. A similar pattern was observed on sputum cells stained for IL-5, RANTES, and eotaxin. Whereas placebo pretreatment caused a 2.4-fold increase in IL-5-positive cells and a 1.7-and 2-fold increase in RANTES and eotaxin-positive cells, respectively, at 7 hours after allergen challenge, the corresponding numbers after pranlukast treatment were 1.5-, 1.0-, and 1.2-fold, respectively. However, this difference was not statistically significant (Table 2) .
Bone Marrow Eo/B cfu
After 2 weeks of treatment with pranlukast, the number (mean Ϯ SD) of IL-5-responsive Eo/B cfu in the bone marrow was 17.3 Ϯ 6.3. This was not different from placebo treatment (17.3 Ϯ 6.1). Allergen inhalation increased the bone marrow Eo/B cfu during placebo treatment to 23.6 Ϯ 6.2. This effect was significantly decreased during pranlukast treatment to 17.7 Ϯ 7.4 (p Ͻ 0.05) (Figure 2 ).
Bone Marrow Progenitor Cell Receptor Expression
We examined the numbers of bone marrow cells expressing CD34 and the numbers of CD34 ϩ cells expressing CCR3. Allergen inhalation preceded by 2 weeks of placebo treatment did Definition of abbreviations: IL ϭ interleukin; RANTES ϭ regulated upon activation, normal T cell expressed and secreted. Immunocytochemistry on sputum cells was performed for EG2, eotaxin, IL-5, and RANTES at baseline, after 2 weeks of treatment before the allergen inhalation (pretreatment), and 7 and 24 hours after allergen inhalation. Pretreatment with pranlukast decreased the allergen-induced increase in positively staining cells compared with placebo. Statistical significance was observed only for EG2 staining. The values are given as mean (SD).
not cause a significant increase in CD34 ϩ cells. However, pranlukast significantly reduced the allergen-induced increase in CD34 ϩ CCR3 ϩ cells compared with placebo (p Ͻ 0.05) ( Table 3) .
DISCUSSION
This study confirms previous findings that treatment with a leukotriene receptor antagonist, pranlukast, decreases the number of total and activated eosinophils in the airway and attenuates their increase after an allergen inhalation. The study also showed for the first time that this was associated with a decrease in the numbers of IL-5-responsive eosinophil cfu and CD34 ϩ CCR3 cells in the bone marrow. This suggests that one of the mechanisms by which leukotriene antagonists decrease allergen-induced airway eosinophil number is by a direct effect on allergen-induced eosinophilopoiesis in the bone marrow.
The ability of specific antagonists of the Cys-LT 1 receptor to decrease airway eosinophil number is well recognized. Six weeks of treatment with montelukast decreased sputum eosinophil number in patients with mildly uncontrolled asthma (14) . Four to six weeks of treatment with pranlukast (26), montelukast (27) , and zafirlukast (28) decreased allergen-induced increase in airway eosinophil number. We observed a similar effect on eosinophil number and activation after 2 weeks of treatment with pranlukast and after an allergen inhalation. We hypothesized, for a number of reasons, that one of the mechanisms would be a direct effect on eosinophilopoeisis and egress of the progenitor cells from the bone marrow. First, allergen inhalation results in increased production of cysteinyl leukotrienes in the airway (29) . Second, CD34
ϩ granulocytic precursors express Cys-LT 1 receptors on their surface (30) . Third, we had demonstrated previously, in vitro, an increase in IL-5-responsive Eo/B cfu when nonadherent mononuclear cells from bone marrow of subjects with atopy were treated with LTD 4 (21) . Finally, LTD 4 evoked calcium fluxes and actin polymerization in CD34 ϩ cells derived from bone marrow of normal subjects and promoted chemotaxis toward it that was inhibited by a Cys-LT 1 receptor antagonist (31) .
Consistent with our hypothesis, we observed two novel effects of the Cys-LT 1 receptor antagonist, pranlukast, on eosinophil progenitor cells. First, the increase in the number of IL-5-responsive cfu after an allergen inhalation was significantly decreased by 2 weeks of treatment with pranlukast, which did not seem to have an effect on the baseline number compared with the placebo treatment arm. The study did not investigate the mechanism of this effect. The effect of a leukotriene receptor antagonist may be direct or indirect. Because cysteinyl leukotrienes may be involved in mediating some of the biological effects of IL-5 (32), pranlukast may interfere with the ability of IL-5 to promote eosinophilopoiesis. This seems unlikely in this study because the nonadherent mononuclear cells from the Cells expressing CD34 and CD34CCR3 on nonadherent mononuclear cells in the bone marrow were enumerated by flow cytometry. There was no effect of allergen or pranlukast on the total number of CD34 ϩ cells. The allergen-induced increase in CD34 ϩ CCR3 ϩ cells observed after placebo treatment was attenuated by pranlukast treatment. The data are presented as mean Ϯ SEM.
* p Ͻ 0.05.
pranlukast-treated subjects were grown in vitro in the presence of optimal concentration of IL-5, unless pranlukast is able to modulate IL-5 signal transduction pathways and make the cells unresponsive or less responsive to the effect of IL-5. There are two major signaling pathways of IL-5 in eosinophils. IL-5 activates Lyn, Syk, and JAK2 and propagates signals through the Rasmitogen-activated protein kinase and Janus kinase-signal transducer and activator transcription factor pathways (33). It is not known whether cysteinyl leukotrienes are involved in either of these pathways. On the basis of recent evidence that they may be upstream of STAT6 signaling in the IL-13 signaling mechanism (34), this is a likely possibility that needs further investigation. The effect of pranlukast on eosinophilopoiesis may also be indirect. Because IL-5 can upregulate Cys-LT 1 receptor expression on HL-60 cells that differentiated into eosinophils (35), they may also increase the expression of Cys-LT 1 receptors on CD34 ϩ cells. Pranlukast may directly prevent IL-5-responsive eosinophil differentiation of the CD34 ϩ cells with increased Cys-LT 1 receptor expression.
The second novel observation in this study was that pranlukast attenuated the allergen-increased increase in the number of CD34 ϩ cells in the bone marrow expressing the eotaxin receptor, CCR3. We confirmed previous observation of CCR3 expression on CD34 ϩ cells (13); however, we did not examine the localization of CCR3 to CD34 ϩ cells that also express IL-5R␣. The CD34 ϩ cells expressing CCR3 show increased chemotaxis toward eotaxin (13) , and this is augmented in the presence of IL-5. It is likely, therefore, that the allergen-induced increase in the levels of IL-5 and eotaxin in the airways of patients with dual asthma response causes the migration of pluripotent undifferentiated hemopoeitic cell from the bone marrow to the airway (36) , where it can undergo local maturation into eosinophils. Our results suggest that cysteinyl leukotrienes are involved in the expression of CCR3 receptors on the progenitor cells. The mechanism was not investigated in this study. Because IL-5 is known to increase CCR3 expression on leukemic cell lines (37) and because treatment with leukotriene receptor antagonists can decrease airway IL-5 levels in murine models of asthma (38, 39) , we postulate that the effect of pranlukast may be indirect by decreasing airway or perhaps bone marrow IL-5 levels. Indeed, airway and bone marrow IL-5 levels increase after an allergen inhalation (40) , and in the present study, pranlukast treatment caused nearly 50% attenuation in the number of sputum cells staining positive for IL-5, 7 hours after an allergen inhalation, compared with placebo. Two weeks of treatment with pranlukast (preallergen) also seemed to cause a trend toward increasing the number of CD34 ϩ cells and CD34 ϩ CCR3 ϩ cells. Because the bone marrow contains a dynamic progenitor cell pool and because we did not perform bone marrow aspiration before the start of treatment, it is difficult to interpret whether this increase represents an increase in bone marrow production or whether it is a reflection of the ability of pranlukast to prevent them from exiting the bone marrow. The latter seems to be the likely possibility.
The effect of pretreatment with a leukotriene antagonist on allergen-induced bone marrow responses seems to be different from that of pretreatment with an inhaled corticosteroid. Seven days of treatment with budesonide decreased IL-5-responsive Eo/B cfu in subjects with asthma; however, unlike in this study, it did not prevent the allergen-induced increase in the numbers of cfu (41) . In other words, although an allergen inhalation was able to overcome the inhibitory effect of inhaled corticosteroids in the growth of IL-5-responsive bone marrow progenitor cells, a leukotriene antagonist seems to be able to prevent it. The most logical explanation is that cysteinyl leukotriene levels increase significantly after an allergen inhalation and may contribute to the stimulation of the bone marrow. It is also possible that allergen may increase the expression of Cys-LT 1 receptor on the progenitor cells making them more responsive to a leukotriene antagonist. The lack of significant effect of 2 weeks of treatment on preallergen Eo/B cfu was surprising considering that the sputum eosinophil counts were decreased with 2 weeks of treatment. It is possible that the role of cysteinyl leukotrienes in eosinophilopoiesis is modest in patients with mild, stable asthma and that other mechanisms such as eosinophil chemoattraction and effect of cytokines are more pronounced. Although it is known that leukotrienes are produced in the bone marrow (42), it is not known whether their levels are increased after an allergen inhalation. We did not measure cysteinyl leukotrienes in the bone marrow in this study, but we plan to do it in future studies. Similar to the previous study (41), we did not find the total number of CD34 ϩ cells to change significantly with allergen inhalation or with treatment.
We also examined the effects of pranlukast treatment on three cytokines/chemokines that are relevant in causing airway eosinophil infiltration. Compared with placebo, pranlukast treatment attenuated the increase in sputum cells staining for IL-5, RANTES, and eotaxin 7 hours after an allergen inhalation. The difference, however, was not statistically significant. One of the reasons is that this was not a primary outcome measure and the study was not powered to show this difference. Second, the variability in the total cell counts in sputum was high, similar to previous reports (1), increasing the noise to signal ratio. However, our observations are consistent with previous reports that have shown leukotriene receptor antagonists to decrease airway IL-5 (38, 39, 43) and RANTES (44) levels in murine models of allergic sensitization.
In summary, the cysteinyl leukotriene receptor antagonist, pranlukast, decreases allergen-induced increase in airway eosinophil by decreasing both eosinophil progenitor cells in the bone marrow and the levels of eosinophilopoietic and chemotactic cytokines in the airway. The reduction in the numbers of IL-5-responsive eosinophil cfu and CD34 ϩ cells expressing CCR3 in the bone marrow suggests a role for cysteinyl leukotrienes in IL-5 signal transduction pathway.
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